Drug Database
HU

human albumin (Kedbumin)

✓ Approved

Kedrion · Cell-based Therapies · Cell-based Therapies

What is human albumin?

human albumin is a cell-based therapies developed by Kedrion. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesKedbumin
CompanyKedrion
Drug ClassCell-based Therapies
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Kedrion

Therapeutic Indications

human albumin is developed for 4 unique indications across 3 therapeutic areas.

Therapeutic AreaConditionPhase
Respiratory, thoracic and mediastinal disordersAcute respiratory distress syndrome✓ Approved
Metabolism and nutrition disordersHypoalbuminaemia✓ Approved
Injury, poisoning and procedural complicationsTraumatic shock✓ Approved
Injury, poisoning and procedural complicationsThermal burn✓ Approved

Related Research Articles

PubMedCurrent opinion in critical care2026-08-30

Albumin and the kidney, a friend or foe.

Shehabi Yahya Y, Balachandran Mayurathan M, Glassford Neil N

Albumin preparations are the most common colloids used in critically ill patients worldwide. This review is to provide the physiological rationale and evidence for benefits and harms in different clinical settings. There is a strong physiological rationale for intravenous albumin administration in critically ill patients. Iso-oncotic and hyperoncotic albumin have both been used for volume resuscitation and to maintain effective plasma volume at an optimal fluid balance. This practice, however, has not proven to be superior to using crystalloids or balanced solutions with no significant reduction in kidney injury or time on vasopressors. In patients with septic shock and hypoalbuminaemia, albeit limitations, subgroup analysis of a randomized trial suggested reduced mortality with albumin supplementation. Similarly, guidelines strongly recommend the use of albumin in hepatic-induced kidney injury and hepatorenal syndrome. Albumin also improved diuresis when combined with diuretics and may improve intradialytic hypotension. Conversely, hyperoncotic albumin infusion increased the risk of kidney injury and red cell transfusion in high-risk cardiac surgery. Hyperoncotic, and albumin administration in general, is a double-edged sword, its use should be tailored to specific clinical scenarios. The use of hyperoncotic albumin in high-risk cardiac surgery should be discouraged.

PMID 42669183
Read full article →
PubMedInternational journal of pharmaceutics: X2026-08-30

Imaging-guided COX-2 inhibition synergizes with photodynamic immunogenic cell death to potentiate checkpoint blockade in colon cancer.

Wu Lina L, Chen Xijun X, He Jiaoling J, Deng Xiaoliang X et al.

Colon cancer is a highly aggressive malignancy lacking specific therapeutic targets. Here, we present a therapeutic strategy that integrates inflammation-driven nanomedicine-based photodynamic therapy (PDT) with immune checkpoint blockade (ICB), with holds the potential to eradicate primary tumors and suppress metastasis. The VC@HSA nanomedicine comprises verteporfin (VER), a photosensitizer that induces immunogenic cell death (ICD), and celecoxib (CXB), an inhibitor of prostaglandin E₂ (PGE₂), co-encapsulated within human serum albumin (HSA). By inhibiting PDT-induced PGE₂ upregulation, CXB enhances ICD while alleviating PGE₂-mediated immunosuppression in the tumor microenvironment. The combination therapy synergizes with anti-PD-L1 treatment to elicit a robust antitumor immune response, characterized by increased infiltration of cytotoxic T lymphocytes. Importantly, the HSA-based nanomedicine enables efficient tumor-targeted delivery and holds potential for imaging-guided therapy due to the intrinsic fluorescence properties of the incorporated components. This coordinated immune activation effectively inhibits the growth of primary and distant colon tumors within a short-term in vivo treatment cycle. Collectively, our findings elucidate the mechanism underlying the co-administration of VER and CXB, demonstrate the advantages of albumin as a superior drug carrier, and establish the combination of VC@HSA with ICB as a promising therapeutic strategy for colon cancer.

PMID 42668486
Read full article →
PubMedFood chemistry2026-08-30

Modulation of gluten network structure, dough rheology, and Chinese steamed bread quality by wheat bran albumin through molecular interactions with gluten proteins.

Zhang Lili L, Guo Fuzhen F, Bian Ke K, Zhang Tingjing T et al.

Impacts of wheat bran albumin (WBA) upon dough rheological properties alongside Chinese steamed bread quality were investigated, with emphasis on its interactions with gluten proteins and gluten network formation. WBA reduced dough viscoelasticity while significantly enhancing extensibility up to 85% with only 0.6% WBA addition, resulting in a 28.4% increase in specific volume of steamed bread. Molecular structure analysis revealed WBA induced gluten protein disaggregation by disrupting disulfide bonds in glutenin, and concomitantly promoted the aggregation through newly formed disulfide bonds and dityrosine cross-links involving gliadin subunits. These corresponded well with the increased endpoints rate and junction density of gluten network. At WBA addition ≤0.6%, protein aggregation predominated, accompanied by synergistically enhanced hydrophobic and hydrogen bonds interactions, together with super alterations in protein secondary and tertiary conformations. Overall, WBA, as a non-gluten protein, exhibited strong potential to regulate gluten network structure and improve flour processing performance.

PMID 42669276
Read full article →
PubMedJournal of nutritional science and vitaminology2026-08-30

Comparative Effects of Guanidinoacetic Acid and Creatine on Body Composition, Muscle Strength, and Protein Metabolism Biomarkers in Older Adults: A Randomized Exploratory Pilot Trial.

Todorovic Nikola N, Nedeljkovic David D, Korovljev Darinka D, Stajer Valdemar V et al.

Creatine supplementation can improve muscle outcomes in older adults, particularly when combined with resistance exercise; however, its efficacy without exercise is less consistent. Guanidinoacetic acid (GAA), the immediate precursor of creatine, may bypass age-related limitations in creatine synthesis and transport and exert distinct effects on muscle energetics and protein metabolism. The main aim of the study was compare the effects of 8 wk of GAA versus creatine supplementation on muscle strength, body composition, and selected protein metabolism biomarkers in older adults. In this randomized, double-blind, exploratory pilot trial, 25 apparently healthy adults aged ≥65 y were assigned to receive GAA (2.0 g/d) or an equimolar dose of creatine monohydrate for 8 wk. Twenty-one participants completed the study (GAA, n=11; creatine, n=10). Handgrip strength, body composition and fluid compartments (via multifrequency bioelectrical impedance analysis), and circulating myostatin, insulin-like growth factor-1, mammalian target of rapamycin, total homocysteine, albumin, and total protein were assessed at baseline and follow-up. Intervention effects were evaluated using repeated-measures ANOVA, and between-group effect sizes for change scores were estimated using Hedges' g with 95% confidence intervals. Handgrip strength increased significantly with GAA (p=0.01) but not with creatine, with a significant time-by-treatment interaction (p=0.04) and a large between-group effect favoring GAA (g=0.91, 95% CI: 0.00 to 1.81). GAA supplementation was associated with significant within-group increases in fat-free mass, body cell mass, muscle mass, and total body water, whereas creatine supplementation did not produce comparable changes. Effect size analyses generally favored GAA for strength, muscle-related indices, and hydration-related compartments, although confidence intervals were wide. Both supplements reduced circulating myostatin, with greater suppression observed with GAA. Creatine supplementation produced a modest reduction in serum albumin that remained within physiological reference ranges. Serum IGF-1 concentrations were below the assay detection limit in most participants, precluding evaluation of the GH-IGF-1 axis. No adverse events were reported, and compliance exceeded 97% in both groups. In this exploratory pilot trial conducted without structured exercise, GAA supplementation was associated with numerically greater improvements in muscle strength and several muscle-related indices compared with creatine; however, these findings are preliminary and hypothesis-generating and require confirmation in adequately powered trials targeting sarcopenia.

PMID 42669527
Read full article →
PubMedFood chemistry: X2026-08-30

Proteomic insights into goat milk serum proteins at varying altitudes in China.

Li Zhaomin Z, Wang Shanshan S, Cao Hanwen H, Yan Yingying Y et al.

Using Astral DIA quantitative proteomics, this study characterized serum protein profiles and potential functions of goat milk from different altitude regions. A total of 1446 proteins were identified, with 1268, 1256, and 1346 proteins detected in high-altitude, mid-altitude, and low-altitude samples, respectively. The high-altitude sample contained 34 unique proteins and showed higher abundances of α-lactalbumin, serum albumin, and polymeric immunoglobulin receptor, whereas the low-altitude sample contained 87 unique proteins and higher abundances of several immune-related proteins, including osteopontin, lactoferrin, immunoglobulin, lysozyme, xanthine oxidase, lactoperoxidase, and GLYCAM1. Differentially expressed analysis identified 453, 452, and 113 differential proteins in high-altitude vs. low-altitude, mid-altitude vs. low-altitude, and high-altitude vs. mid-altitude comparisons, respectively. KEGG analysis showed that carbohydrate metabolism was enriched in comparisons involving the low-altitude sample, whereas amino acid metabolism was enriched between high-altitude and mid-altitude samples. Notably, HIF-1 signaling pathway was enriched in the high-altitude sample, suggesting hypoxia-associated proteomic adaptation.

PMID 42668543
Read full article →
PubMedJapanese journal of infectious diseases2026-08-30

Evaluation of the Virucidal Activity of Chlorine Dioxide against Hepatitis B Virus.

Chen Ming M, Pereira Caroline Donzeli CD, Watashi Koichi K, Shibata Takashi T et al.

Hepatitis B virus (HBV) remains a major global public health concern, with numerous nosocomial and occupational outbreaks reported. Preventing indirect HBV transmission through effective disinfection is crucial. This study evaluated the virucidal activity of chlorine dioxide (ClO₂) against HBV and compared it with sodium hypochlorite (NaClO). Pretreatment of HBV with ClO₂ at 10, 100, and 250 ppm (mg/L) for 1 min reduced hepatitis B surface antigen (HBsAg) release to 65.5%, 21.9%, and 7.0%; hepatitis B core (HBc)-positive cells to 59.1%, 27.0%, and 6.6%; intracellular HBV RNA to 71.5%, 31.6%, and 3.0%; and extracellular HBV DNA to 82.2%, 42.6%, and 14.1%, respectively. At identical concentrations, NaClO produced smaller reductions. In the presence of organic matter, no significant reduction in ClO₂ activity against HBV was observed. ClO₂ demonstrated approximately 2.2-fold greater anti-HBV potency than NaClO with and without bovine serum albumin and sheep erythrocytes. Neutralizer, cell-permissiveness, and ultrafiltration controls supported direct viral inactivation. These findings indicate that ClO₂ showed stronger in vitro anti-HBV activity than NaClO within the tested concentration range and conditions.

PMID 42669543
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about human albumin